We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+11.07%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.52B
AUM Growth
+$425M
Cap. Flow
+$155M
Cap. Flow %
2.81%
Top 10 Hldgs %
32.71%
Holding
141
New
18
Increased
27
Reduced
28
Closed
15

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$109M
2
UTHR icon
United Therapeutics
UTHR
+$89M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$87.1M
4
BAX icon
Baxter International
BAX
+$79M
5
CI icon
Cigna
CI
+$41.9M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$57.1M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$47M
3
BLU
BELLUS Health Inc.
BLU
+$36.8M
4
PGNY icon
Progyny
PGNY
+$33.3M
5
SYK icon
Stryker
SYK
+$27.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.75%
2 Industrials 1.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
Sarepta Therapeutics
SRPT
$1.65B
$74.9M 1.36%
654,000
-211,100
-24% -$27.2M
MDGL icon
27
Madrigal Pharmaceuticals
MDGL
$12.4B
$74.3M 1.35%
+321,569
New +$87.1M
CRNX icon
28
Crinetics Pharmaceuticals
CRNX
$8.88B
$71.2M 1.29%
3,950,796
– –
CMPX icon
29
Compass Therapeutics
CMPX
$355M
$71.1M 1.29%
22,362,850
– –
XTNT icon
30
Xtant Medical Holdings
XTNT
$59.1M
$68M 1.23%
73,114,592
– –
TERN
31
DELISTED
Terns Pharmaceuticals
TERN
$66.7M 1.21%
7,619,135
– –
RCM
32
DELISTED
R1 RCM Inc. Common Stock
RCM
$63.5M 1.15%
3,441,000
+1,691,000
+97% +$27.5M
SIBN icon
33
SI-BONE Inc
SIBN
$809M
$61.9M 1.12%
2,292,531
-626,923
-21% -$15.3M
KROS icon
34
Keros Therapeutics
KROS
$196M
$60.9M 1.1%
1,514,734
-164,683
-10% -$7.22M
SPRY icon
35
ARS Pharmaceuticals
SPRY
$552M
$58.6M 1.06%
8,740,887
– –
VRTX icon
36
Vertex Pharmaceuticals
VRTX
$124B
$58.2M 1.05%
165,400
-12,200
-7% -$4.11M
SCPH
37
DELISTED
scPharmaceuticals
SCPH
$56.7M 1.03%
5,559,528
– –
SNDX icon
38
Syndax Pharmaceuticals
SNDX
$1.68B
$53M 0.96%
2,530,240
+818,565
+48% +$17M
PCVX icon
39
Vaxcyte
PCVX
$7.68B
$50.3M 0.91%
1,007,148
+277,709
+38% +$13.2M
PRLD icon
40
Prelude Therapeutics
PRLD
$364M
$49.1M 0.89%
10,909,256
+869,565
+9% +$5.2M
EW icon
41
Edwards Lifesciences
EW
$49.3B
$48.6M 0.88%
515,000
-115,000
-18% -$10M
NTRA icon
42
Natera
NTRA
$35.8B
$47.4M 0.86%
973,581
– –
NBIX icon
43
Neurocrine Biosciences
NBIX
$18.2B
$46.1M 0.84%
489,000
– –
CI icon
44
Cigna
CI
$79.1B
$45.2M 0.82%
+161,000
New +$41.9M
XENE icon
45
Xenon Pharmaceuticals
XENE
$6.17B
$42.2M 0.76%
1,096,000
-53,100
-5% -$2.11M
ALPN
46
DELISTED
Alpine Immune Sciences Inc
ALPN
$42M 0.76%
4,081,592
– –
PMVP icon
47
PMV Pharmaceuticals
PMVP
$58.1M
$41.1M 0.74%
6,563,077
– –
ZBH icon
48
Zimmer Biomet
ZBH
$18.7B
$35.7M 0.65%
+245,000
New +$33.3M
RPTX
49
DELISTED
Repare Therapeutics
RPTX
$35.2M 0.64%
3,322,488
– –
GRCL
50
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$34.4M 0.62%
9,033,726
-464,048
-5% -$1.3M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2023 Portfolio in Review

As of Q2 2023, OrbiMed held 141 positions worth $5.52B, up 8.3% from $5.09B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed's Q2 2023 filing shows 18 new, 27 increased, 28 reduced and 15 closed positions. Its largest new stake was ACELYRIN: 5,326,302 shares worth $111M. The largest sale was Bristol-Myers Squibb, an estimated $57.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Industrials.

  • OrbiMed's largest Q2 2023 buy was ACELYRIN: 5,326,302 shares worth $111M.
  • OrbiMed added most to Baxter International in Q2 2023, an estimated $79M increase.
  • OrbiMed's biggest Q2 2023 reduction was Bristol-Myers Squibb, cutting an estimated $57.1M.
  • OrbiMed fully exited Chinook Therapeutics, Inc. Common Stock in Q2 2023, selling an estimated $47M.
  • OrbiMed's ten largest holdings make up 33% of its $5.52B portfolio in Q2 2023.
  • OrbiMed opened 18 new positions and closed 15 in Q2 2023.
  • OrbiMed's portfolio value rose 8.3% quarter-over-quarter to $5.52B.

Based on OrbiMed's 13F filing for Q2 2023, filed 14 Aug 2023.